SCHEMBL29211489

SCHEMBL29211489

CCCN1C(=O)CCC1=S

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.40
MGLL Q99685 2/20 0.40
CYP19A1 P11511 3/20 0.36
CHRM2 P08172 5/20 0.33
CHRM4 P08173 5/20 0.33
CHRM5 P08912 5/20 0.33
CHRM1 P11229 5/20 0.33
CHRM3 P20309 5/20 0.33
DRD2 P14416 4/20 0.33
DRD4 P21917 4/20 0.33
DRD3 P35462 4/20 0.33
ALDH1A1 P00352 2/20 0.33
THRB P10828 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
ATAD2 Q6PL18 1/20 0.32
ADRB2 P07550 1/20 0.31
ADRB1 P08588 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11835650 0.86 CHRM2 (0.34) FAAHMGLLCHRM2CHRM4CHRM5
SCHEMBL10931036 0.84 MGLL (0.54) FAAHMGLLCYP19A1
SCHEMBL31252627 0.84 MGLL (0.54) FAAHMGLLCYP19A1
SCHEMBL1825898 0.84 FAAH (0.50) FAAHMGLLCYP19A1CHRM2CHRM4
SCHEMBL11836587 0.82 FAAH (0.42) FAAHMGLLCHRM2CHRM4CHRM5
SCHEMBL11591030 0.82
SCHEMBL11837219 0.82 MEN1 (0.38) FAAHMGLLCHRM2CHRM4CHRM5
SCHEMBL11850667 0.80 MGLL (0.41) FAAHMGLLCHRM2CHRM4CHRM5
SCHEMBL11848036 0.80 MGLL (0.41) FAAHMGLLCHRM2CHRM4CHRM5
SCHEMBL11837926 0.80 MGLL (0.41) FAAHMGLLCHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240352056-A1 Improved methods for production of cyclic guanosine-monophosphate analogues MIRECA MEDICINES GMBH (DE) 2024-10-24 US disclosed
CN-117999269-A Improved process for producing cyclic guanosine monophosphate analogues 米雷卡医药有限公司 2024-05-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240352056-A1 Improved methods for production of cyclic guanosine-monophosphate analogues GMPS, CGAS, AMPD3 FAAH 3927/4885MGLL 1216/4885CYP19A1 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.